Companies Dominating the Anti-Asthma TDM Assay Kits Landscape
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bio-Techne Corporation
- Svar Life Science AB
- Thermo Fisher Scientific Inc.
- Eagle Biosciences, Inc.
- Merck KGaA
- Elabscience Biotechnology Inc.
- MyBioSource Inc.
- Creative Diagnostics
- Diagnostic Automation (Cortez Diagnostics, Inc.)
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of anti-asthma TDM assay kits is assessed at USD 22.11 billion.
The anti-asthma TDM assay kits market size was valued at USD 20.16 billion in 2024 and is likely to cross USD 42.48 billion by 2037, registering more than 5.9% CAGR during the forecast period i.e., between 2025-2037. The rising cases of asthma, rising air pollution, and growing demand for anti-asthma drugs will fuel the market growth.
North America industry is set to hold largest revenue share by 2037, attributed to increasing count of patients suffering from asthma.
The major players in the market are F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Svar Life Science AB, Thermo Fisher Scientific Inc., Eagle Biosciences, Inc., Merck KGaA, Elabscience Biotechnology Inc., MyBioSource Inc., Creative Diagnostics, Diagnostic Automation (Cortez Diagnostics, Inc.)
